Miracell Expands its Middle Eastern Market with “Smart M-Cell 2” Following Europe
Miracell to Target the Middle East with ‘Smart M-Cell 2’ Following Europe Participating in Dubai International Medical Device Exhibition Following its success in the European market, stem cell specialist Miracell (CEO Shin Hyun-soon) is targeting the Arab market. Miracell announced on the 19th that it will participate in the “Dubai International Medical Device Exhibition (Arab Health 2022)” held in Dubai from the 24th to the 27th. The Dubai International Medical Device Exhibition, held in 1976 and now in its 47th year, is the largest medical device exhibition in the Middle East and one of the world’s four largest medical device exhibitions. Last year, it attracted 110,000 attendees from 64 countries. Miracell will showcase its “Smart M-Cell 2,” a “state-of-the-art bio-stem cell extraction system” developed using domestic technology. Furthermore, through membership in the Cellpia Global Platform (CGP), the company has built an organic network with doctors and medical staff at hospitals and clinics both domestically and internationally, sharing specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing for safe stem cell regenerative medicine treatments at hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “At an exhibition held in Germany, Miracell secured contracts from buyers who expressed satisfaction with Miracell’s bio-stem cell system, which received European CE certification, and its therapeutic effects for psoriasis and other conditions.” He added, “We will continue our success in Europe in the Middle East and expand globally.” He added, “We are currently pursuing global patents, including those from the FDA, in over 40 countries, so our future sales outlook is bright.”
Miracell Recruiting for Early Mild Dementia Stem Cell Clinical Trial
Miracell Recruiting for Early-Medium Dementia Stem Cell Clinical Trial Stem cell company Miracell (CEO Shin Hyun-soon) announced on the 19th that it will conduct a stem cell clinical trial for dementia with the neurosurgery team at Hanyang University Hospital. The number of young patients with early-onset dementia in their 30s and 40s has been increasing. Since many patients rely solely on medication, Miracell explained that it and the neurosurgery team at Hanyang University Hospital decided to conduct a clinical trial targeting early-onset dementia patients.This trial focuses on managing blood vessels, which are the pathways that supply oxygen and nutrients. Since damage to blood vessels can lead to abnormalities in all brain diseases, CD34+, platelets, cytokines, and VGEF growth factors will be injected directly into the blood vessels, transporting them to the brain. This clinical trial will be conducted under the title “The Effects of Autologous Blood-Derived Stem Cells in Patients with Vascular Dementia (Prospective, Randomized, Controlled Trial).” Accordingly, participants in the clinical trial are currently being recruited for patients with vascular dementia. Vascular dementia is the second most common disease after Alzheimer’s, but currently, there is no clear treatment beyond managing risk factors such as high blood pressure and diabetes. Therefore, this study will selectively isolate cells from the patient’s own blood and inject them safely into the body to assess neurological prognosis, neuroprotective effects, and improvement in dementia symptoms. The stem cell extraction for this study will be conducted under the leadership of the neurosurgery team at Hanyang University Hospital, using the SMART M-CELL2 and BSC regenerative medicine biosystems developed by Miracell.CEO Shin Hyun-soon stated, “Smart M-CELL2 and BSC, which have been approved by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, have been approved not only in Korea but also in the EU. Using this device, we selectively extract up to 98% of superior biological molecules and cells, and inject them directly into the body through a safe route, eliminating concerns about side effects.” Clinical trial subjects are selected after completing a baseline screening. Patients with early-onset dementia aged 40 to 70 who have had vascular dementia for more than three months, have shown minimal improvement despite current medication, and have not seen any improvement in symptoms.
Miracell Hosts CGP Academy on Autologous Bone Transplantation and Bone Marrow Concentration Techniques
Miracell hosts CGP Academy on “Autologous Bone Transplantation and Bone Marrow Concentration Techniques”Orthopedic surgeon Dr. Chan-il Jeong will present, explaining treatment and surgical techniques. Stem cell specialist Miracell announced on the 24th that it held a Global Platform (CGP) Academy on the topic of “Autologous Bone Transplantation and Bone Marrow Concentration Techniques.” The lecture was delivered by Dr. Chan-il Jeong, an orthopedic surgeon and director of Cellpia Clinic, a leading stem cell education institution, who personally explained actual treatment and surgical techniques to medical staff from CGP member hospitals and clinics. The lecture covered pelvic anatomy, bone marrow collection methods, and the resulting differences in outcomes. Following the lecture, Dr. Jeong vividly demonstrated the bone marrow stem cell extraction process from an actual patient in the operating room, after prior consent had been obtained. Based on the lecture, he explained the essentials and details, addressing any questions the attending medical staff had. The bone marrow stem cells were concentrated and isolated using Miracell’s “SMART M-CELL2”BmSC, a dedicated bone marrow stem cell kit certified as a new health technology by the Ministry of Health and Welfare. SMART M-CELL2 is a system that extracts large quantities of stem cells by centrifuging bone marrow blood. It is currently used by major hospitals across various medical specialties. Director Jeong emphasized, “The key is to extract stem cells easily and safely using a special trocar through a posterior approach, without side effects such as pain, bleeding, or nerve damage.” He added, “In particular, the instrument must be inserted while avoiding the iliolumbar ligament and the superior gluteal cutaneous nerve. During the procedure in the prone position, it is important to determine whether the ilium is displaced posteroinferiorly or anterosuperiorly, and to check the needle’s internal and external rotational displacement to accurately target the target point.” This bone marrow extraction technique training attracted significant interest from doctors at CGP member hospitals and clinics from the application stage, with more medical staff participating than the actual number of applicants. Unlike blood, bone marrow extraction requires a high level of technical expertise, and the amount of stem cells that can be extracted varies depending on the extraction method. Miracell’s CGP Amatemi is a platform for sharing stem cell medical technology and knowledge through an organic network with various member hospitals and clinics. Launched in 2019, Miracell Inc. strives to lead the way in specialized stem cell treatment and research, and contribute to disease treatment. It actively engages in education on a variety of topics with hospital and clinic staff. CGP provides education, technology transfer, medical equipment setup, and marketing services to hospitals both domestically and internationally, to ensure safer stem cell regenerative medicine treatments. By Sangjun Ahn